New hope for kids with progeria: experimental drug combo enters mid-stage trial
NCT ID NCT06775041
First seen Jan 26, 2026 · Last updated May 17, 2026 · Updated 14 times
Summary
This study tests an experimental drug called progerinin, given together with the standard medicine lonafarnib, in children with Hutchinson-Gilford progeria syndrome (a rare disease that causes rapid aging). The goal is to find the best dose and check if the combination is safe and tolerable. About 10 children aged 1 year and older will take either lonafarnib alone or lonafarnib plus progerinin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUTCHINSON-GILFORD PROGERIA SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.